Best Non Tech Stocks
Discover investment opportunities in Best Non Tech Stocks using our Smart AI Filter.
AI is processing your request...
AI is analyzing your request
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Non Tech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Non Tech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Non Tech Stocks using our Smart AI Filter.
8 stocks found for "Best Non Tech Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
---|---|---|---|---|---|---|
0.35 | ±16.4% | 24.0 | 2.86% | |||
0.73 | ±17.7% | 28.3 | 0.67% | |||
0.52 | ±21.0% | 23.8 | 2.48% | |||
0.33 | ±17.2% | 21.7 | 2.51% | |||
0.32 | ±25.0% | 16.5 | 2.85% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.40 | ±19.0% | 23.3 | 2.41% | |||
0.61 | ±21.1% | 14.3 | 3.57% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What advantages does Johnson & Johnson (JNJ) offer to healthcare sector investors?
A: Johnson & Johnson, a healthcare giant, is diversified across pharmaceuticals, medical devices, and consumer health, offering stability and resilience in economic downturns. Its R&D investments and global reach further enhance its competitive edge.
Q: How does Procter & Gamble's (PG) business model appeal to value investors?
A: Procter & Gamble's diverse product portfolio in consumer goods and strong brand equity provide steady cash flow. Historically, it has maintained robust dividend payouts, appealing to investors seeking value and income stability.
Q: Why might some investors consider Coca-Cola (KO) a reliable dividend stock?
A: Coca-Cola is known for its iconic brand and global distribution network, which supports consistent revenue. The company has a history of increasing dividends annually, making it attractive for income-focused investors.
Q: What factors contribute to PepsiCo's (PEP) resilience in economic cycles?
A: PepsiCo's diversified product range, including beverages and snacks, aids in offsetting market volatilities. Its strong market presence and innovation in health-focused products contribute to its cyclic resilience.
Q: What potential benefits does Merck (MRK) offer in the pharmaceutical sector?
A: Merck's robust pipeline in oncology and vaccines, coupled with successful existing products like Keytruda, provides strong growth prospects. It emphasizes innovation, which can be appealing amid global health challenges.
Q: How does investing in Home Depot (HD) align with real estate growth trends?
A: Home Depot benefits from increased home improvement spending during housing market upswings. The company's extensive store network and strong customer service foster customer loyalty and revenue growth.
McDonald's workers won't see a benefit from the "no tax on tips" change in the Big Beautiful Bill. But the new law points to an "uneven playing field" for restaurants, CEO Chris Kempczinski said.
Read moreMichal Lev-Ram, Fortune contributing editor, joins 'The Exchange' to discuss how Silicon Valley is responding to recent comments from the White House, why tech land is not for stakes in these companies and much more.
Read more